Sign In
Buy RDY
$13.02
-0.0100 (-0.0767%)
At Close: Jun 03, 2026
Dr. Reddy's Q3 Earnings Match Estimates, Revenues Rise Y/Y
10:31am, Thursday, 22'nd Jan 2026
RDY posts flat Q3 earnings, while revenues miss estimates as global generics growth lagged, pressured by weaker North America sales.
Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript
04:26pm, Wednesday, 21'st Jan 2026
Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Antihistamineeyedrop--Dr. Reddy's launched Olopatadine Hydrochloride Ophthalmic Solution USP 0.7% (OTC), a generic equivalent of Extra-Str
3 Generic Drug Stocks to Watch Amid Changing U.S. Landscape
09:26am, Monday, 08'th Dec 2025
Generic drugmakers face U.S. pricing pressure, but TEVA, SDZNY and RDY gain momentum through complex generics and biosimilars.
Dr. Reddy's receives exclusive rights to develop and commercialise Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China Under the terms, Immutep to receive upfront
Fisher Asset Management LLC Sells 522,987 Shares of Dr. Reddy’s Laboratories Ltd $RDY
04:36am, Wednesday, 03'rd Dec 2025
Fisher Asset Management LLC trimmed its position in shares of Dr. Reddy's Laboratories Ltd (NYSE: RDY) by 20.6% during the undefined quarter, according to its most recent 13F filing with the Securitie
American Century Companies Inc. Acquires 133,045 Shares of Dr. Reddy’s Laboratories Ltd $RDY
03:20am, Wednesday, 03'rd Dec 2025
American Century Companies Inc. boosted its holdings in Dr. Reddy's Laboratories Ltd (NYSE: RDY) by 14.5% in the undefined quarter, according to its most recent filing with the Securities and Exchange
BANGALORE, India--(BUSINESS WIRE)-- #AurigeneOncology--Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112.
Contrasting Dr. Reddy’s Laboratories (NYSE:RDY) and Bausch Health Cos (NYSE:BHC)
01:19am, Sunday, 16'th Nov 2025
Dr. Reddy's Laboratories (NYSE: RDY - Get Free Report) and Bausch Health Cos (NYSE: BHC - Get Free Report) are both medical companies, but which is the better investment? We will compare the two busin
Dr. Reddy's: Underappreciated Future Amid Exaggerated Headwinds
02:02pm, Wednesday, 29'th Oct 2025
Dr. Reddy's Laboratories remains a compelling buy due to underappreciated growth in biosimilars and GLP-1 segments, despite near-term headwinds. RDY's Q2 FY26 results showed modest revenue growth, wit
Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues
12:36pm, Monday, 27'th Oct 2025
RDY posts a Q2 earnings and revenue beat as global generics drive growth, while new launches and biosimilar advances shape its pipeline.
Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript
06:57pm, Friday, 24'th Oct 2025
Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q2 2026 Earnings Call October 24, 2025 10:00 AM EDT Company Participants Richa Periwal - Head of Investor Relations and Analytics Mannam Venkatanarasimham
My Top 5 Biotech Stocks Big Pharma Could Buy Next
01:29pm, Monday, 06'th Oct 2025
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of
Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.
08:16am, Monday, 18'th Aug 2025
Extrovis AG Bahnhof Park 46340, Baar, Switzerland Media Relations Contact Madhu Marur [email protected] Press Re
Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues
12:25pm, Thursday, 24'th Jul 2025
RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
